Supernus Pharmaceuticals (SUPN) Return on Equity: 2012-2025
Historic Return on Equity for Supernus Pharmaceuticals (SUPN) over the last 14 years, with Sep 2025 value amounting to -0.02%.
- Supernus Pharmaceuticals' Return on Equity fell 8.00% to -0.02% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.02%, marking a year-over-year decrease of 8.00%. This contributed to the annual value of 0.08% for FY2024, which is 7.00% up from last year.
- Latest data reveals that Supernus Pharmaceuticals reported Return on Equity of -0.02% as of Q3 2025, which was down 129.28% from 0.06% recorded in Q2 2025.
- In the past 5 years, Supernus Pharmaceuticals' Return on Equity registered a high of 0.15% during Q1 2021, and its lowest value of -0.02% during Q3 2025.
- In the last 3 years, Supernus Pharmaceuticals' Return on Equity had a median value of 0.05% in 2023 and averaged 0.03%.
- Per our database at Business Quant, Supernus Pharmaceuticals' Return on Equity fell by 11bps in 2021 and then rose by 8bps in 2025.
- Over the past 5 years, Supernus Pharmaceuticals' Return on Equity (Quarterly) stood at 0.07% in 2021, then remained steady at 0.07% in 2022, then dropped by 7bps to 0.00% in 2023, then rose by 7bps to 0.07% in 2024, then declined by 8bps to -0.02% in 2025.
- Its Return on Equity stands at -0.02% for Q3 2025, versus 0.06% for Q2 2025 and 0.06% for Q1 2025.